Anti Cd 20 Ocrevus denied as duplicate or overlapping therapy by Humana?

Humana's specific coverage criteria for anti cd20 ocrevus are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana May Deny Ocrelizumab as Duplicate Therapy

A "duplicate therapy" denial from Humana means the plan's system identified that you are currently covered for — or have recently received — another treatment that Humana considers to target the same condition through a sufficiently similar mechanism. For ocrelizumab (Ocrevus), this most often occurs when a patient is transitioning from another B-cell-depleting or immunosuppressive therapy, or when a concurrent medication appears in claims data. Humana is asserting that covering both drugs simultaneously is not medically appropriate.

## Why This Denial Is Appealable

A duplicate-therapy determination is a clinical judgment, and clinical judgments are subject to full appeal. Your neurologist — not Humana's claims algorithm — is best positioned to explain why ocrelizumab is necessary and distinct from any other therapy in your regimen. Common grounds for reversal include: the other drug is being used for a different condition; the overlap is a brief, clinically managed transition period; or the mechanism of action and clinical role of ocrelizumab differs in a way that is meaningful for your care.

## Your Federal Appeal Rights

• Internal appeal: ACA §2719 and ERISA §503 entitle you to a full-and-fair internal review. File within the deadline on your denial letter, commonly 180 days for ERISA plans.
• External review: If the internal appeal is denied, an independent external review is available under ACA §2719, generally within approximately four months of final internal denial.
• Expedited option: If you are mid-infusion course and a gap in therapy would cause clinical harm, request expedited review; decisions are typically required within 72 hours.

## Documentation to Gather

1. Current medication list with indications — a complete, annotated list showing every drug you take and the specific condition each one treats. 2. Prescriber letter explaining the clinical rationale for ocrelizumab alongside any other immunomodulating therapy, including why the combination or transition is medically appropriate. 3. Transition plan documentation — if you are switching from another agent, chart notes that describe the washout or overlap plan and the clinical reason for the timing. 4. Diagnosis confirmation — neurologist records, MRI results, and clinical notes confirming the MS diagnosis and current disease status. 5. Humana's duplicate-therapy policy — obtain the written policy to understand exactly what criteria triggered the denial and what evidence is needed to refute it.

## Criteria-Mapping Approach

Identify from Humana's policy what two drugs are characterized as duplicative. In your appeal, address each of the policy's overlap criteria in turn. For each criterion, cite the specific clinical record that distinguishes ocrelizumab's role. If the other drug serves a different indication, include that documentation explicitly. The goal is to show the reviewer that the clinical picture your prescriber sees is not captured by a claims-data comparison.

## Next Step

Start by obtaining the full denial letter with the specific drugs Humana identified as duplicative. Confirm with your neurologist whether the overlap is intentional and clinically documented, then build the appeal around that documented rationale.